Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: Report of 21 cases

American Journal of Surgical Pathology

Volumn 32, Issue 3, 2008, Pages 461-467

  Osunkoya, Adeboye O ^a   Hansel, Donna E ^b   Sun, Xinlai ^c   Netto, George J ^a   Epstein, Jonathan I ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Lakewood Pathology Associates   (United States)

Author keywords

Aberrant diffuse expression of p63; AMACR HMWCK p63 cocktail; Atrophic glands; Needle biopsy; Prostate cancer; Radical prostatectomy

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; CYTOKERATIN; EOSIN; HEMATOXYLIN; PROTEIN P63;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR WEIGHT; NEEDLE BIOPSY; NUCLEOLUS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; SEMINAL VESICLE; SPINDLE CELL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; HISTOCYTOCHEMISTRY; HUMANS; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 40849126971     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318157020e     Document Type: Article

References (31)

1. Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol. 2004;17:307-315.
2. Googe PB, McGinley KM, Fitzgibbon JF. Anticytokeratin antibody 34 beta E12 staining in prostate carcinoma. Am J Clin Pathol. 1997;107:219-223.
3. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol. 2005;22:88-104.
4. Hameed O, Humphrey PA. p63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning. Am J Clin Pathol. 2005;124:708-715.
5. Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol. 2005;29:579-587.
6. Hosler GA, Epstein JI. Basal cell hyperplasia: an unusual diagnostic dilemma on prostate needle biopsies. Hum Pathol. 2005;36:480-485.
7. Jiang Z, Li C, Fischer A, et al. Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005;123:231-236.
8. Little NA, Jochemsen AG. P63. Int J Biochem Cell Biol. 2002;34:6-9.
9. Mastropasqua MG, Pruneri G, Renne G, et al. Basaloid cell carcinoma of the prostate. Virchows Arch. 2003;443:787-791.
10. Molinie V, Fromont G, Sibony M, et al. Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol. 2004;17:1180-1190.
11. Molinie V, Herve JM, Lebret T, et al. Value of the antibody cocktail anti p63+anti p504s for the diagnosis of prostatic cancer. Ann Pathol. 2004;24:6-16.
12. Molinie V, Herve JM, Lugagne PM, et al. P63 and p504s cocktail is useful in ambiguous lesions of the prostate. Histopathology. 2004;44:403-404.
13. Nagle RB, Ahmann FR, McDaniel KM, et al. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res. 1987;47:281-286.
14. Oliai BR, Kahane H, Epstein JI. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am J Surg Pathol. 2002;26:1151-1160.
15. Ostrzega N, Cheng L, Layfield LJ. Keratin immunoreactivity in fine-needle aspiration of the prostate: an aid in the differentiation of benign epithelium from well-differentiated adenocarcinoma. Diagn Cytopathol. 1988;4:38-41.
16. Parsons JK, Gage WR, Nelson WG, et al. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001;58:619-624.
17. Pinthus JH, Pacik D, Ramon J. Diagnosis of prostate cancer. Recent Results Cancer Res. 2007;175:83-99.
18. Rioux-Leclercq NC, Epstein JI. Unusual morphologic patterns of basal cell hyperplasia of the prostate. Am J Surg Pathol. 2002;26:237-243.
19. Rubio J, Ramos D, Lopez-Guerrero JA, et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol. 2005;48:745-751.
20. Saito K, Kawakami S, Okada Y, et al. Spatial and isoform specific p63 expression in the male human urogenital tract. J Urol. 2006;176:2268-2273.
21. Shah IA, Schlageter MO, Stinnett P, et al. Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate. Mod Pathol. 1991;4:220-224.
22. Shah RB, Zhou M, LeBlanc M, et al. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002;26:1161-1168.
23. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000;157:1769-1775.
24. Stewart JM, Fleshner N, Cole H, et al. Comparison of Annexin II, p63 and AMACR immunoreactivity in prostatic tissue: a tissue microarray study. J Clin Pathol. 2007;60:773-780.
25. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. 2002;15:1302-1308.
26. Wu HH, Lapkus O, Corbin M. Comparison of 34betaE12 and P63 in 100 consecutive prostate carcinoma diagnosed by needle biopsies. Appl Immunohistochem Mol Morphol. 2004;12:285-289.
27. Yang A, Kaghad M, Wang Y, et al. P63, a P53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305-316.
28. Yang XJ, Lecksell K, Gaudin P, et al. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol. 1999;23:147-152.
29. Yang XJ, Tretiakova MS, Sengupta E, et al. Florid basal cell hyperplasia of the prostate: a histological, ultrastructural, and immunohistochemical analysis. Hum Pathol. 2003;34:462-470.
30. Zhou M, Shah R, Shen R, et al. Basal cell cocktail (34betaE12+ p63) improves the detection of prostate basal cells. Am J Surg Pathol. 2003;27:365-371.
31. Zhou M, Magi-Galluzzi C, Epstein JI. Prostate basal cell lesions can be negative for basal cell keratins: a diagnostic pitfall. Anal Quant Cytol Histol. 2006;28:125-129.